The Analysis of the Effects of Executive Functions, Working Memory and Other Factors on Medication Adherence in Elderly Men with Benign Prostatic Hyperplasia and Overactive Bladder Symptoms

Author(s): Kirill Kosilov*, Irina Kuzina, Vladimir Kuznetsov, Liliya Kosilova, Marina Ivanovskaya, Ekaterina Kosilova

Journal Name: Current Aging Science

Volume 13 , Issue 1 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Aim: Evaluation of the executive function and working memory influence, as well as the general state of memory, on adherence to Benign Prostatic Hyperplasia (BPH) and overactive bladder symptoms treatment in elderly men.

Background: The influence of the executive function and working memory on treatment adherence in older men with BPH has not been studied enough.

Objective: To determine the level of influence of various factors on the treatment adherence in older men with BPH.

Methods: The executive function and working memory evaluation, as well as a general memory assessment, were carried out using the Wisconsin Test, the Wechsler Memory Scale, and the California Verbal Test. Hierarchical and simultaneous regressions were calculated to study the effect of executive function and working memory.

Results: After the end of the study, the symptoms of hyperactive bladder significantly decreased, the symptoms of evacuation did not change significantly, and the cognitive status of the patients remained unchanged. The predictor variables significantly influencing adherence of elderly men to BPH and overactive bladder (OAB) treatment are executive function and working memory composite (β = .33, p & lt; .05), severe symptoms of lower urinary tract (-.34, p & lt; .05), and age (-.27, p & lt; .05).

Conclusion: The status of executive function and working memory, as well as the age and severity of the pathological symptoms of the lower urinary tract, should be taken into account when predicting the risks of rejecting BPH and OAB treatment in elderly patients.

Keywords: Elderly men, medication adherence, executive functions, working memory, benign prostatic hyperplasia, overactive bladder.

[1]
Auffenberg GB, Helfand BT, McVary KT. Established medical therapy for benign prostatic hyperplasia. Urol Clin North Am 2009; 36(4): 443-59.
[http://dx.doi.org/10.1016/j.ucl.2009.07.004] [PMID: 19942044]
[2]
Alawamlh OAH, Goueli R, Lee RK. Lower urinary tract symptoms, benign prostatic hyperplasia, and urinary retention. Med Clin North Am 2018; 102(2): 301-11.
[http://dx.doi.org/10.1016/j.mcna.2017.10.005] [PMID: 29406059]
[3]
Liao L, Schaefer W. Qualitative quality control during urodynamic studies with TSPs for cystometry in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Int Urol Nephrol 2014; 46(6): 1073-9.
[http://dx.doi.org/10.1007/s11255-013-0633-6] [PMID: 24375436]
[4]
Park YH, Kim TH, Lee SW, Chung BH, Cho JS, Lee JY. Treatment patterns and patient reported outcomes in benign prostatic hyperplasia patients with overactive bladder symptoms. Low Urin Tract Symptoms 2017; 9(2): 75-81.
[http://dx.doi.org/10.1111/luts.12112] [PMID: 28394492]
[5]
Wang H, Chang Y, Liang H. Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. Pak J Med Sci 2017; 33(4): 988-92.
[http://dx.doi.org/10.12669/pjms.334.12757] [PMID: 29067079]
[6]
Wada N, Matsumoto S, Kita M, Hashizume K, Kakizaki H. Improvement of overactive bladder symptoms and bladder ischemia with dutasteride in patients with benign prostatic enlargement. Low Urin Tract Symptoms 2015; 7(1): 37-41.
[http://dx.doi.org/10.1111/luts.12047] [PMID: 26663650]
[7]
Seo DH, Kam SC, Hyun JS. Impact of lower urinary tract symptoms/benign prostatic hyperplasia treatment with tamsulosin and solifenacin combination therapy on erectile function. Korean J Urol 2011; 52(1): 49-54.
[http://dx.doi.org/10.4111/kju.2011.52.1.49] [PMID: 21344031]
[8]
Yamanishi T, Asakura H, Seki N, Tokunaga S. Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: A multicenter, randomized, open-label, controlled trial. Int J Urol 2017; 24(7): 525-31.
[http://dx.doi.org/10.1111/iju.13359] [PMID: 28466585]
[9]
Homma Y, Gotoh M, Kawauchi A, et al. Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia. Int J Urol 2017; 24(10): 716-29.
[http://dx.doi.org/10.1111/iju.13401] [PMID: 28748576]
[10]
Hanuš T, Zámečník L, Doležal T, Karmazínová Z. Occurrence of overactive bladder in patients with benign prostatic hyperplasia in the Czech Republic. Urol Int 2011; 86(4): 407-13.
[11]
Esin E, Ergen A, Cankurtaran M, et al. Influence of antimuscarinic therapy on cognitive functions and quality of life in geriatric patients treated for overactive bladder. Aging Ment Health 2015; 19(3): 217-23.
[http://dx.doi.org/10.1080/13607863.2014.922528] [PMID: 25555041]
[12]
Cindolo L, Pirozzi L, Fanizza C, et al. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. Eur Urol 2015; 68(3): 418-25.
[http://dx.doi.org/10.1016/j.eururo.2014.11.006] [PMID: 25465970]
[13]
Nichol MB, Knight TK, Wu J, Barron R, Penson DF. Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. J Urol 2009; 181(5): 2214-21.
[http://dx.doi.org/10.1016/j.juro.2009.01.033] [PMID: 19296986]
[14]
Kosilov K, Loparev S, Kuzina I, Shakirova O, Zhuravskaya N, Lobodenko A. The effective tool for self-assessment of adherence to treatment in patients with benign prostatic obstruction and overactive bladder symptoms. Aging Male 2017; 20(1): 39-44.
[http://dx.doi.org/10.1080/13685538.2016.1247435] [PMID: 28074677]
[15]
Kosilov KV, Alexandrovich LS, Gennadyevna KI, Viktorovna SO, Sergeevna ZN, Ivanovich AI. Social, economic, and medical factors associated with solifenacin therapy compliance among workers who suffer from lower urinary tract symptoms. Int Neurourol J 2016; 20(3): 240-9.
[http://dx.doi.org/10.5213/inj.1632520.260] [PMID: 27706009]
[16]
Drake MJ, Bowditch S, Arbe E, et al. A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands. BMC Urol 2017; 17(1): 36.
[http://dx.doi.org/10.1186/s12894-017-0226-2] [PMID: 28532455]
[17]
Anger JT, Goldman HB, Luo X, et al. Patterns of medical management of overactive bladder (OAB) and benign prostatic hyperplasia (BPH) in the United States. Neurourol Urodyn 2018; 37(1): 213-22.
[http://dx.doi.org/10.1002/nau.23276] [PMID: 28455944]
[18]
Veenboer PW, Bosch JL. Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review. J Urol 2014; 191(4): 1003-8.
[http://dx.doi.org/10.1016/j.juro.2013.10.046] [PMID: 24140548]
[19]
Gong M, Dong W, Huang G, et al. Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis. Curr Med Res Opin 2015; 31(9): 1781-92.
[http://dx.doi.org/10.1185/03007995.2015.1074067] [PMID: 26211817]
[20]
Kosilov KV, Loparev S, Kuzina I, Shakirova O, Zhuravskaya N, Lobodenko A. Treatment compliance of working persons to high-dose antimuscarinic therapies: a randomized trial. Ther Adv Urol 2016; 8(4): 239-48.
[http://dx.doi.org/10.1177/1756287216652030] [PMID: 27928426]
[21]
Kosilov KV, Loparev SA, Ivanovskaya MA, Kosilova LV. Randomized controlled trial of cyclic and continuous therapy with trospium and solifenacin combination for severe overactive bladder in elderly patients with regard to patient compliance. Ther Adv Urol 2014; 6(6): 215-23.
[http://dx.doi.org/10.1177/1756287214544896] [PMID: 25435915]
[22]
Kosilov KV, Loparev SA, Ivanovskaya MA, Kosilova LV. Comparative effectiveness of combined high-dosed Trospium and Solifenacin for severe OAB symptoms in age-related aspect. Int J Urol Nurs 2015; 9(2): 108-13.
[http://dx.doi.org/10.1111/ijun.12076]
[23]
Kosilov KV, Loparev SA, Ivanovskaya MA, Kosilova LV. Effectiveness of solifenacin and trospium for managing of severe symptoms of overactive bladder in patients with benign prostatic hyperplasia. Am J Men Health 2016; 10(2): 157-63.
[http://dx.doi.org/10.1177/1557988315595692]
[24]
Kosilov K, Kuzina I, Kuznetsov V, et al. Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage. Aging Male 2018; 21(2): 121-9.
[25]
Fuster JM. The prefrontal cortex--an update: time is of the essence. Neuron 2001; 30(2): 319-33.
[http://dx.doi.org/10.1016/S0896-6273(01)00285-9] [PMID: 11394996]
[26]
Raz NB. Ed. (Ed.). (2000). Aging of the brain and its impact on cognitive performance: Integration of structural and functional findings. In F. I. M. Craik & T. A. Salthouse (Eds.), The handbook of aging and cognition (pp. 1-90). Mahwah, NJ: Erlbaum.
[27]
Insel K, Morrow D, Brewer B, Figueredo A. Executive function, working memory, and medication adherence among older adults. J Gerontol B Psychol Sci Soc Sci 2006; 61(3): 102-7.
[28]
Alosco ML, Spitznagel MB, van Dulmen M, et al. Cognitive function and treatment adherence in older adults with heart failure. Psychosom Med 2012; 74(9): 965-73.
[http://dx.doi.org/10.1097/PSY.0b013e318272ef2a] [PMID: 23115344]
[29]
Coyne KS, Zyczynski T, Margolis MK, Elinoff V, Roberts RG. Validation of an overactive bladder awareness tool for use in primary care settings. Adv Ther 2005; 22(4): 381-94.
[http://dx.doi.org/10.1007/BF02850085] [PMID: 16418145]
[30]
Wu JM, Fulton RG, Amundsen CL, Knight SK, Kuppermann M. Patient preferences for different severities of and treatments for overactive bladder. Female Pelvic Med Reconstr Surg 2011; 17(4): 184-9.
[http://dx.doi.org/10.1097/SPV.0b013e318223c8ad] [PMID: 22453849]
[31]
Tanabe MK, Whitaker AM, O’Callaghan ET, Murray J, Houskamp BM. Intellectual ability as a predictor of performance on the Wisconsin Card-Sorting Test. Appl Neuropsychol Child 2014; 3(4): 275-83.
[http://dx.doi.org/10.1080/21622965.2012.757700] [PMID: 24083565]
[32]
Davis JJ, Wall JR. Examining verbal memory on the word memory test and california verbal learning test-second edition. Arch Clin Neuropsychol 2014; 29(8): 747-53.
[http://dx.doi.org/10.1093/arclin/acu030] [PMID: 25064762]
[33]
Figueredo AJ, McKnight PE, McKnight KM, Sidani S. Multivariate modeling of missing data within and across assessment waves. Addiction 2000; 95(Suppl. 3): S361-80.
[http://dx.doi.org/10.1046/j.1360-0443.95.11s3.6.x] [PMID: 11132363]
[34]
Singh I, Agarwal V, Garg G. ‘Tamsulosin and darifenacin’ versus ‘tamsulosin monotherapy’ for ‘BPH with accompanying overactive bladder’. J Clin Diagn Res 2015; 9(6): PC08-11.
[http://dx.doi.org/10.7860/JCDR/2015/12526.6019] [PMID: 26266159]
[35]
Romancik M, Pandian S, Drake MJ. Tamsulosin/solifenacin fixed-dose combination tablet for the treatment of male lower urinary tract symptoms. Drugs Today 2014; 50(12): 803-11.
[http://dx.doi.org/10.1358/dot.2014.50.12.2247444] [PMID: 25588085]
[36]
Li MC, Wang ZY, Yang J, et al. Efficacy and safety of solifenacin plus tamsulosin oral controlled absorption system in men with lower urinary tract symptoms: a meta-analysis. Asian J Androl 2015; 17(1): 124-34.
[http://dx.doi.org/10.4103/1008-682X.137685] [PMID: 25337836]
[37]
Sicras-Mainar A, Rejas J, Navarro-Artieda R, et al. Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis. Int Urogynecol J Pelvic Floor Dysfunct 2014; 25(4): 485-92.
[http://dx.doi.org/10.1007/s00192-013-2250-4] [PMID: 24196653]
[38]
Sexton CC, Notte SM, Maroulis C, et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract 2011; 65(5): 567-85.
[39]
Oefelein MG. Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder. Drug Saf 2011; 34(9): 733-54.
[http://dx.doi.org/10.2165/11592790-000000000-00000] [PMID: 21830836]
[40]
Cai JL, Zhou Z, Yang Y, Yan YF, Jing S, Na YQ. Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: A double-blind, placebo-controlled, randomized clinical trial. Chin Med J 2016; 129(24): 2899-906.
[http://dx.doi.org/10.4103/0366-6999.195461] [PMID: 27958220]
[41]
Kosilov K, Loparev S, Ivanovskaya M, Kosilova L. Additional correction of OAB symptoms by two anti-muscarinics for men over 50 years old with residual symptoms of moderate prostatic obstruction after treatment with Tamsulosin. Aging Male 2015; 18(1): 44-8.
[http://dx.doi.org/10.3109/13685538.2014.951922] [PMID: 25136746]
[42]
Dellis AE, Papatsoris AG, Keeley FX Jr, Bamias A, Deliveliotis C, Skolarikos AA. Tamsulosin, solifenacin, and their combination for the treatment of stent-related symptoms: A randomized controlled study. J Endourol 2017; 31(1): 100-9.
[http://dx.doi.org/10.1089/end.2016.0663] [PMID: 27809592]
[43]
Kosilov KV, Loparev SA, Ivanovskaya MA, Kosilova LV. Decrease of risk of developing symptoms of OAB in elderly men and women treated with loop diuretic for hypertensive disease using solifenacin. Curr Aging Sci 2014; 7(3): 229-34.
[http://dx.doi.org/10.2174/1874609808666141210101344] [PMID: 25495568]
[44]
Wiedemann A, Maykan R, Pennekamp J, Hirsch J, Heppner H. Potential cognitive alterations after treatment of benign prostate syndrome. Investigations on transurethral electroresection and 180 W GreenLight XPS laser therapy. Z Gerontol Geriatr 2015; 48(5): 446-51.
[http://dx.doi.org/10.1007/s00391-014-0819-2] [PMID: 25287677]
[45]
Chancellor M, Boone T. Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neurosci Ther 2012; 18(2): 167-74.
[http://dx.doi.org/10.1111/j.1755-5949.2011.00248.x] [PMID: 22070184]
[46]
Kerdraon J, Robain G, Jeandel C, et al. Impact on cognitive function of anticholinergic drugs used for the treatment of overactive bladder in the elderly. Prog Urol 2014; 24(11): 672-81.
[http://dx.doi.org/10.1016/j.purol.2014.06.003] [PMID: 25214448]
[47]
Royall DR, Palmer R, Chiodo LK, Polk MJ. Declining executive control in normal aging predicts change in functional status: the Freedom House Study. J Am Geriatr Soc 2004; 52(3): 346-52.
[http://dx.doi.org/10.1111/j.1532-5415.2004.52104.x] [PMID: 14962147]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 13
ISSUE: 1
Year: 2020
Page: [72 - 80]
Pages: 9
DOI: 10.2174/1874609812666190927153152

Article Metrics

PDF: 16
HTML: 2